The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes

  1. Eun Seok Kang, MD, PHD12,
  2. Bong Soo Cha, MD, PHD12,
  3. Hyeong Jin Kim, MD3,
  4. Hae Jin Kim, MD4,
  5. So Hun Kim, MD1,
  6. Kyu Yeon Hur, MD1,
  7. Hyun Joo Lee, MD1,
  8. Wan Sub Shim, MD1,
  9. Chul Woo Ahn, MD, PHD12 and
  10. Hyun Chul Lee, MD, PHD12
  1. 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
  2. 2Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea
  3. 3Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
  4. 4Department of Endocrinology and Metabolism, Ajou University College of Medicine, Suwon, Korea
  1. Address correspondence and reprint requests to Hyun Chul Lee, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong Seodaemun-Gu, Seoul, 120-752, Korea. E-mail: endohclee{at}yumc.yonsei.ac.kr

Abstract

OBJECTIVE—The aim of this study was to examine the effects of perilipin gene (PLIN) polymorphisms on weight gain with rosiglitazone treatment in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—A total of 160 type 2 diabetic patients were treated with rosiglitazone (4 mg/day) for 12 weeks in addition to their previous medications, which were unchanged. Four single nucleotide polymorphisms (SNPs) at the PLIN locus were genotyped: PLIN 6209T>C, PLIN 11482G>A, PLIN 13041A>G, and PLIN 14995A>T.

RESULTS—Although fasting plasma glucose and HbA1c levels decreased; mean body weight increased significantly after rosiglitazone treatment. Among the four SNPs tested, only the PLIN 11482G>A polymorphism was associated with weight gain from rosiglitazone treatment. In addition, there was a significant difference in the increase in the body weight among the genotypes. Patients with the 11482A/A genotype showed less increase in body weight than those with other genotypes.

CONCLUSIONS—These data suggest that genetic variations in the perilipin gene can affect weight gain associated with rosiglitazone treatment in patients with type 2 diabetes.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted March 5, 2006.
    • Received December 15, 2006.
« Previous | Next Article »Table of Contents

This Article

  1. doi: 10.2337/dc05-2466 Diabetes Care June 2006 vol. 29 no. 6 1320-1324
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)

Current Issue

  1. December 2009, 32 (12)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care